|本期目录/Table of Contents|

[1]戴为正,吴美娜,傅懋林,等.普拉克索联合高频重复经颅磁刺激治疗早期帕金森病合并抑郁患者的临床疗效观察[J].医学研究与战创伤救治(原医学研究生学报),2021,23(6):592-595.[doi:10.3969/j.issn.1672-271X.2021.06.007]
　DAI Wei-zheng,WU Mei-na,FU Mao-lin,et al.Observation on clinical effects of pramipexole combined with high-frequency repetitive transcranial magnetic stimulation (rTMS) in the treatment of patients suffered from early Parkinson’s disease (PD) and depression[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2021,23(6):592-595.[doi:10.3969/j.issn.1672-271X.2021.06.007]
点击复制

普拉克索联合高频重复经颅磁刺激治疗早期帕金森病合并抑郁患者的临床疗效观察()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第23卷
期数:
2021年6期
页码:
592-595
栏目:
临床研究
出版日期:
2021-12-15

文章信息/Info

Title:
Observation on clinical effects of pramipexole combined with high-frequency repetitive transcranial magnetic stimulation (rTMS) in the treatment of patients suffered from early Parkinson’s disease (PD) and depression
作者:
戴为正; 吴美娜; 傅懋林; 叶迎安; 何文钦; 阮志芳
作者单位：362000泉州，解放军联勤保障部队第九一○医院神经内科（戴为正、吴美娜、傅懋林、叶迎安、何文钦、阮志芳）
Author(s):
DAI Wei-zheng;  WU Mei-na;  FU Mao-lin;  YE Ying-an; HE Wen-qin; RUAN Zhi-fang
（Department of Neurology, the 910th Hospital of the Joint Logistics Support Force，PLA，Quanzhou 362000, Fujian, China）
关键词:
重复经颅磁刺激; 普拉克索; 帕金森病; 抑郁
Keywords:
repetitive transcranial magnetic stimulation;  pramipexole;  Parkinson’s disease;  depression
分类号:
R742.5
DOI:
10.3969/j.issn.1672-271X.2021.06.007
文献标志码:
A
摘要:
目的观察比较普拉克索联合高频重复经颅磁刺激（rTMS）治疗与单独使用普拉克索治疗早期帕金森病合并抑郁患者的疗效及安全性。方法选取2016年1月-2019年7月解放军联勤保障部队第九一○医院收治的帕金森病合并抑郁的患者80例，完全随机分为药物组和联合治疗组，每组40例。药物组患者在原有药物治疗基础上加用普拉克索。联合治疗组在加用普拉克索治疗同时，连续使用高频刺激入组患者双侧前额背外侧（DLPFC）区14 d。在治疗前及治疗后14 d、28 d分别行帕金森病统一评定量表第Ⅲ部分（UPDRS Ⅲ）评分及汉密尔顿抑郁量表-24（HAMD-24）评估，并记录2组治疗过程中出现的不良反应。结果药物组治疗后14 d HAMD-24评分[（15.22±3.74）分]、28 d HAMD-24评分[（12.18±4.52）分]较治疗前评分[（22.72±4.75）分]改善（P＜0.05）；联合治疗组治疗后14 d HAMD-24评分[（11.83±3.36）分]、28 d HAMD-24评分[（10.55±2.73）分]较治疗前评分[（23.84±4.91）分]改善（P＜0.05）。药物组治疗后14 d UPDRSⅢ评分[（17.95±3.74）分]、28 d UPDRSⅢ评分[（18.44±3.81）分]较治疗前UPDRS Ⅲ评分[（20.65±2.07）分]改善（P＜0.05）；联合治疗组治疗后14 d UPDRSⅢ评分[（14.42±3.35）分]、28 d UPDRSⅢ评分[(15.58±2.79)分]较治疗前UPDRS Ⅲ评分[（21.03±1.98）分]改善（P＜0.05）。与药物组比较，治疗后14、28 d联合治疗组UPDRS评分、HAMD-24评分改善更明显，2组同时间点比较差异有统计学意义（P＜0.05）。结论普拉克索联合高频rTMS用于帕金森病合并抑郁症患者治疗效果优于普拉克索单药治疗，安全性高。
Abstract:
ObjectiveTo observe and compare the efficacy and safety of high-frequency rTMS combined with pramipexole versus pramipexole alone in the treatment of patients suffered from early PD and depression.Methods80 patients suffered from PD and depression were selected and divided into drug group and combined treatment group randomly. For patients in the drug group, pramipexole was added in addition to the original drugs. For patients in the combined treatment group, in addition to the original drugs and pramipexole, the high-frequency stimulation was adopted continuously on their bilateral dorsal lateral prefrontal cortex (DLPFC) for 14 days. The unified PD rating scale part Ⅲ (UPDRS Ⅲ) score and Hamilton depression scale-24 (HAMD-24) assessment were performed before and on the 14th and 28th day after treatment, respectively. Adverse reactions in the two groups were recorded. ResultsThe HAMD-24 score [(15.22±3.74) points] for 14 days and HAMD-24 score [(12.18±4.52) points] for 28 days after treatment in the drug group were improved compared with the scores before treatment [(22.72±4.75) points] (P＜0.05); the HAMD-24 score [(11.83±3.36) points] for 14 days and HAMD-24 score [(10.55±2.73) points] for 28 days after treatment in the combined treatment group were improved compared with the scores before treatment [(23.84±4.91) points] (P<0.05). The UPDRS Ⅲ score [(17.95±3.74) points] for 14 days and UPDRS Ⅲ score [(18.44±3.81) points] for 28 days after treatment in the drug group were improved compared with the UPDRS Ⅲ scores [(20.65±2.07) points] before treatment (P＜0.05) ); the UPDRS Ⅲ score [(14.42±3.35) points] for 14 days and UPDRS Ⅲ score [(15.58±2.79) points] for 28 days after treatment in the combined treatment group were improved compared with the UPDRS Ⅲ scores [(21.03±1.98) points] before treatment (P<0.05). Compared with the drug group, the UPDRSIII score and HAMD-24 score in the combined treatment group improved more significantly for 14 and 28 days after treatment, and the difference between the two groups at the same time point was statistically significant (P<0.05).ConclusionThe high-frequency rTMS combined with pramipexole is superior to pramipexole alone in the treatment of patients suffered from PD and depression with higher safety.

参考文献/References:

[1]陈生弟. 中国帕金森病治疗指南(第三版)[J]. 中华神经科杂志, 2014,47(6):428-433.
[2]陈永平, 商慧芳. 2016中国帕金森病诊断标准解读[J]. 中国实用内科杂志, 2017,37(2):124-126.
[3]Goodarzi Z, Mrklas KJ, Roberts DJ, et al. Detecting depression in Parkinson disease: A systematic review and meta-analysis[J]. Neurology, 2016,87(4):426-37.
[4]辛陈琦, 张承武, 李林. 帕金森病发病机制与治疗研究进展[J]. 医学研究生学报, 2019,32(6):646-651.
[5]何婧, 苏闻. 重复经颅磁刺激在治疗帕金森病抑郁中的应用[J]. 中国神经免疫学和神经病学杂志, 2017,24(5):362-365.
[6]中华医学会神经病学分会帕金森病及运动障碍学组, 中国医师协会神经内科医师分会帕金森病及运动障碍专业. 中国帕金森病的诊断标准(2016版)[J]. 中华神经科杂志, 2016,49(4):268-271.
[7]Ryan M, Eatmon CV, Slevin JT. Drug treatment strategies for depression in Parkinson disease[J]. Expert Opin Pharmacother, 2019,20(11):1351-1363.
[8]Maillet A, Krack P, Lhommée E, et al. The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson’s disease[J]. Brain, 2016,139(Pt 9):2486-2502.
[9]娄毓婷. 帕金森病合并重症抑郁的静息态功能磁共振研究[D]. 杭州：浙江大学,2015.
[10]周梦露, 金光勇, 邵佳辉, 等. 普拉克索治疗帕金森病抑郁的Meta分析[J]. 浙江医学, 2019,41(1):59-62，74.
[11]Escalona R, Fawcett J. Pramipexole in Treatment Resistant-Depression, Possible Role of Inflammatory Cytokines[J]. Neuropsychopharmacology, 2017,42(1):363.
[12]张深山, 叶凯文, 高镇松. 普拉克索治疗帕金森病伴发抑郁障碍临床疗效与安全性[J]. 广东医学, 2010,31(7):908-910.
[13]朱社华. 普拉克索治疗老年帕金森病伴发抑郁的临床疗效分析[J]. 中国社区医师, 2017,33(10):74，76.
[14]宁征远. 重复低频经颅磁刺激联合阿戈美拉汀治疗老年抑郁症的临床疗效[J]. 东南国防医药, 2019,21(1):62-64.
[15]王晓雪, 刘欣欣, 张风林, 等. 重复经颅磁刺激联合生物反馈对帕金森病运动与非运动症状的影响[J]. 广东医学, 2016,37(5):695-697.
[16]祁娜, 王炳臣, 徐天朝. 重复经颅磁刺激治疗重度抑郁症的效果及对负性自动思维和执行功能的影响[J]. 东南国防医药, 2021,23(2):155-158.
[17]Makkos A, Pál E, Aschermann Z, et al. High-Frequency Repetitive Transcranial Magnetic Stimulation Can Improve Depression in Parkinson’s Disease: A Randomized, Double-Blind, Placebo-Controlled Study[J]. Neuropsychobiology, 2016,73(3):169-177.

相似文献/References:

[1]于苏文,郑秀琴,陈红霞,等.高频重复经颅磁刺激治疗帕金森病临床疗效观察[J].医学研究与战创伤救治(原医学研究生学报),2010,12(02):109.
　YU Su-wen,ZHENG Xiu-qin,CHEN Hong-xia,et al.Clinicalal study of treating Parkinsons disease by repetitively transcranial magnetic stimulation[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2010,12(6):109.
[2]祁娜,王炳臣,徐天朝.重复经颅磁刺激治疗重度抑郁症的效果及对负性自动思维和执行功能的影响[J].医学研究与战创伤救治(原医学研究生学报),2021,23(02):155.[doi:10.3969/j.issn.1672-271X.2021.02.010]
　QI Na,WANG Bing-chen,XU Tian-chao.The effect of rTMS on severe depression and its influence on negative automatic thinking and executive function[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2021,23(6):155.[doi:10.3969/j.issn.1672-271X.2021.02.010]

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2021-12-15